Compare Adaptive Biotechnologies Corp (ADPT) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Boeing Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Boeing Co trades at $224.21 (market cap $182.63B). The key difference: Boeing Co is far larger — about 54.8× Adaptive Biotechnologies Corp's market cap, and Boeing Co pays a 0.03% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BA | |
|---|---|---|
Market Cap | $3.33B | $182.63B |
Sector | Health | Industrials |
52-Week High | $22.37 | $252.15 |
52-Week Low | $10.24 | $179.12 |
Enterprise Value | $3.19B | $208.94B |
Volume | — | 7,591,579 |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Boeing (BA) trades at $231.68, up 2.29% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $268.33. The company returned to profitability in 2025 with $2.24B net income on $89.46B revenue, though valuation ratios like P/E of 92.7 remain elevated. Recent news highlights defense contract wins and production expansion, including a new 737 assembly line.
Outlook: Boeing's recovery trajectory offers upside potential driven by operational improvements and strong backlog, but high debt, thin margins, and execution risks pose challenges. Analyst sentiment is predominantly bullish, yet investors should weigh valuation concerns against growth catalysts in the aerospace cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
